about
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trialSeasonal vaccination against malaria: a potential use for an imperfect malaria vaccine.Space-time clustering of childhood malaria at the household level: a dynamic cohort in a Mali villageSafety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali.Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult MaliansSafety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trialPhase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children.A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali.Evaluation of the Mercy weight estimation method in Ouelessebougou, MaliEffect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, MaliNon-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay.Increase in EPI vaccines coverage after implementation of intermittent preventive treatment of malaria in infant with Sulfadoxine -pyrimethamine in the district of Kolokani, Mali: results from a cluster randomized control trial.Malaria morbidity in children in the year after they had received intermittent preventive treatment of malaria in Mali: a randomized control trialLack of allele-specific efficacy of a bivalent AMA1 malaria vaccinePrimary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and MaliIntermittent preventive treatment of malaria in children: a qualitative study of community perceptions and recommendations in Burkina Faso and Mali.Plasmodium falciparum clearance with artemisinin-based combination therapy (ACT) in patients with glucose-6-phosphate dehydrogenase deficiency in Mali.Anaemia in a phase 2 study of a blood stage falciparum malaria vaccineImmunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunizedThe African Vaccine-Preventable Diseases Network: a vaccine advocacy initiativeA multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT studyAnalysis of Preventive Interventions for Malaria: Exploring Partial and Complete Protection and Total and Primary Intervention EffectsSeasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa.Risk factors associated with abscess formation among patient with leg erysipelas (cellulitis) in sub-Saharan Africa: a multicenter study.The implementation of malaria intermittent preventive trialtreatment with sulphadoxine-pyrimethamine in infants reduced all-cause mortality in the district of Kolokani, Mali: results from a cluster randomized controlRepeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impactEfficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger.Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria.Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.Short report: elevated levels of alanine aminotransferase and hepatitis A in the context of a pediatric malaria vaccine trial in a village in Mali.Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in MaliEfficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial.A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in MaliAssociation of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children.Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease
P50
Q28477050-EA314024-BC3F-4E00-9B1E-7DFAF87EA0CDQ30234589-91FD593B-933E-4497-BCB3-FC49BAD63FDAQ33264226-625CF4C6-28E7-4904-8155-CA6213C741A8Q33264523-F10AF962-17E0-4696-B17F-6840B84FE8A5Q33278087-28B29FD7-6867-4A44-B697-93FCF00E3CE1Q33302903-84A037D3-FABE-4DAB-853E-F15C19193AB4Q33316023-AB2FF491-8E30-46BC-BEB6-D2DFA8E809B4Q33319552-3DC4DF88-0697-40E2-AD8E-A4D119EF9929Q33598040-43EED291-69AA-4C39-8634-222D8698BCF5Q33645358-4636F994-CD86-46B3-AD08-7DA3ABEEF9BDQ33845371-73D120C9-CB65-4B3F-B9A0-9864A0CDBB1EQ33916707-3CC8926F-8199-4565-9146-7BD387E53135Q33939405-D9C7C2A0-E1B7-4FC6-9D78-B2A97ED47788Q33964491-B5730591-25F2-48AD-8272-7F88485027CBQ33999551-90D0B7B3-4918-4218-AC68-5D8FD7F40217Q34011922-35E70B28-15B7-42CC-8D7D-FF40D0FD3CD1Q34082225-BE6EBCDF-5799-4C74-A365-6D22B189A8A8Q34160143-F3A3034C-55CB-495C-9E7C-6AEB7573F961Q34193509-8B1165B5-4FBE-482F-81B7-0B95CCB2BF4CQ34398049-62E4EE34-CE0D-4015-ABBB-4DE4AB8137E8Q34564544-A376B8F0-FF05-4B93-9BB5-84F4A1F399B8Q34612788-51F26BB2-2436-4640-8CDF-4C08038F6BAEQ35444613-93404482-F989-4A9E-B5FD-5FE2722EE57AQ35661786-55B87D0C-34A9-4205-9BD5-0DCBC1E7507DQ35713083-59DC1BC8-EAE4-4974-9D95-B173D96A1D01Q35748391-401E86CB-955E-4366-AD55-BCFD436D3E32Q35868504-823D34BF-6D18-4200-B264-01FD5A05DF2AQ35984647-1F4BBC35-207E-483D-A989-3D1FF87ADAA1Q36080127-EB1684A7-9ED2-49CE-8159-1881FF0A0B97Q36173444-14801C6B-6DBA-44C5-B622-DC577CC23E52Q36256464-B1110C5D-B482-45A3-B3D4-8EB3DB9BE6A5Q36501878-90FCB334-4FEA-45A2-8023-1ADF975A6634Q36558721-7E35EA3E-C6A8-44E1-91E6-83303AFF1D0FQ36817781-EDBC21FF-BC84-44B6-9095-8CBC41F2A82EQ37019155-A3DAA02C-D4C2-47A9-B31A-B2DC2A142DD8Q37117352-6CC6713F-B2D3-4109-977E-612C9AF0C00FQ37182225-3E4C8CEA-6466-4ABE-9025-67577D6EF9B6Q37267850-4899AC73-B79E-42F2-AED7-33A768C91252Q37335488-995C88D8-0601-4E02-865A-C2C547493134Q37339874-6A1BC204-A049-4424-941D-A4F333617614
P50
name
Alassane Dicko
@en
Alassane Dicko
@nl
type
label
Alassane Dicko
@en
Alassane Dicko
@nl
prefLabel
Alassane Dicko
@en
Alassane Dicko
@nl